List of Excipients in Branded Drug SPRITAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aprecia Pharmaceuticals LLC	SPRITAM	levetiracetam	43485-101	BUTYLATED HYDROXYANISOLE
Aprecia Pharmaceuticals LLC	SPRITAM	levetiracetam	43485-101	CELLULOSE, MICROCRYSTALLINE
Aprecia Pharmaceuticals LLC	SPRITAM	levetiracetam	43485-101	GLYCERIN
Aprecia Pharmaceuticals LLC	SPRITAM	levetiracetam	43485-101	MANNITOL
Aprecia Pharmaceuticals LLC	SPRITAM	levetiracetam	43485-101	POLYSORBATE 20
Aprecia Pharmaceuticals LLC	SPRITAM	levetiracetam	43485-101	POVIDONE

Spritam Excipient Strategy and Commercial Opportunities in 3D-Printed Levetiracetam

Last updated: August 16, 2026

Spritam is an orally disintegrating levetiracetam tablet built around Aprecia Pharmaceuticals’ ZipDose powder-bed 3D-printing platform. Its commercial differentiation comes from rapid disintegration, high-dose loading, and water-assisted administration rather than a novel active ingredient. The core excipient opportunity is therefore process-specific: mannitol, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate must support powder flow, layer deposition, tablet porosity, mechanical handling, rapid wetting, and acceptable mouthfeel. [1]

The largest commercial opportunities are in platform-enabling excipients, specialty-grade mannitol, disintegrant systems, taste-masking materials, contract development and manufacturing, and follow-on orally disintegrating levetiracetam products. The main constraint is that generic competition can target the active ingredient and dosage form without reproducing Aprecia’s exact excipient combination or 3D-printing process.

What is Spritam and why do its excipients matter?

Spritam is a prescription orally disintegrating tablet containing levetiracetam in 250 mg, 500 mg, 750 mg, and 1,000 mg strengths. FDA approved Spritam under NDA 207958 in August 2015. The product is intended to dissolve with a sip of liquid and is not designed to be swallowed whole like a conventional tablet. [1,2]

Its excipient system has to solve several formulation problems simultaneously:

Formulation requirement	Commercial relevance
High drug loading	Levetiracetam doses reach 1,000 mg per tablet
Rapid liquid penetration	Drives short disintegration time
Low tablet density and high porosity	Supports ZipDose performance
Adequate green strength	Prevents breakage during handling and packaging
Powder flow and layer uniformity	Supports reliable 3D-printing throughput
Acceptable oral texture	Reduces grittiness and residue
Chemical and physical stability	Protects shelf life and dose uniformity

A conventional directly compressed tablet can use many standard excipient systems. A powder-bed printed tablet has a narrower design space because the formulation must print consistently before it is converted into a finished dosage form.

What excipients are used in Spritam?

FDA labeling identifies mannitol, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate as inactive ingredients in Spritam. [1]

Mannitol

Mannitol is the principal bulking and mouthfeel excipient. It is attractive for orally disintegrating products because it has a relatively clean taste, provides a cooling sensation, and dissolves readily in water.

For Spritam, mannitol likely performs several functions:

• Provides bulk for the high-dose tablet.
• Supports rapid dissolution and wetting.
• Improves oral acceptability relative to less palatable polyols or inorganic fillers.
• Helps create a porous tablet structure.
• Contributes to tablet fracture and friability behavior.

Mannitol grade selection is commercially important. Particle-size distribution, morphology, moisture content, flowability, and compressibility can materially affect powder-bed deposition. A supplier that offers a controlled particle-size grade validated for powder spreading could capture more value than a commodity mannitol supplier.

Croscarmellose sodium

Croscarmellose sodium is a superdisintegrant. It promotes liquid uptake and tablet breakup through swelling and wicking.

In a porous printed dosage form, its role may be different from its role in a conventional compressed tablet. The printed structure already provides channels for liquid penetration. Croscarmellose sodium must therefore be balanced against excessive swelling, powder segregation, tablet friability, and mouthfeel.

The commercial opportunity is a low-use-level, high-efficiency disintegrant grade that maintains rapid disintegration without increasing tablet roughness or causing visible residue.

Colloidal silicon dioxide

Colloidal silicon dioxide is primarily a glidant and flow aid. It can improve powder movement, reduce cohesion, and help maintain a more uniform powder layer during printing.

Its value in a 3D-printing formulation is process-related. Small changes in surface area, moisture adsorption, and mixing energy can affect:

• Powder spreading.
• Layer thickness.
• Binder penetration.
• Dose uniformity.
• Tablet surface quality.
• Equipment fouling.

This creates a niche opportunity for pharmaceutical-grade colloidal silicon dioxide supplied with tighter flow and moisture specifications, supported by powder rheology data rather than only conventional compendial testing.

Magnesium stearate

Magnesium stearate is generally used as a lubricant. In a printed dosage form, its level and blending conditions require control because excessive hydrophobic lubricant can reduce wetting and delay disintegration.

The relevant development question is not simply whether magnesium stearate reduces friction. It is whether the lubricant protects equipment and improves powder handling without materially reducing liquid penetration or weakening interparticle bonding.

A supplier able to provide low-lubricity-impact grades, or a formulation partner able to replace magnesium stearate with an alternative lubricant, could address a specific performance bottleneck.

How does ZipDose change excipient selection?

ZipDose is a powder-based 3D-printing technology that deposits a liquid binder onto successive powder layers. The resulting tablet has a porous structure and can accommodate high doses while remaining rapidly disintegrating. Aprecia has described the platform as capable of producing large, fast-dissolving doses that are difficult to manufacture using conventional tableting methods. [3]

The excipient strategy differs from ordinary oral solid dosage development in four ways.

Powder-bed behavior becomes a critical quality attribute

Standard tablet development focuses on compression, ejection, hardness, friability, and dissolution. Powder-bed printing adds:

• Hausner ratio and Carr index.
• Shear-cell flow.
• Dynamic flow energy.
• Spreadability.
• Layer uniformity.
• Binder penetration.
• Powder recycling performance.

Excipient suppliers can create value by qualifying materials against these parameters and supplying formulation-ready grades.

Porosity replaces some conventional disintegration engineering

Conventional orally disintegrating tablets often depend heavily on superdisintegrants, compression force, and tablet architecture. Printed tablets can obtain fast disintegration from internal porosity. This may reduce the required disintegrant level, but it increases sensitivity to powder packing and binder distribution.

A formulation that maximizes porosity may become too fragile. A formulation that improves mechanical strength may lose rapid disintegration. This tradeoff favors co-development rather than simple excipient substitution.

Dose loading increases the importance of taste management

Levetiracetam is administered at doses that can reach 1,500 mg twice daily in adults under labeling guidance. Spritam itself contains up to 1,000 mg in one tablet. [1] A high-dose orally disintegrating product can expose patients to substantial active pharmaceutical ingredient in the mouth.

Mannitol contributes to mouthfeel, but future products may require additional taste-masking approaches, including:

• Polymer coating of levetiracetam particles.
• Ion-exchange resins.
• Lipid barriers.
• Microencapsulation.
• Flavor systems compatible with rapid aqueous dispersion.
• Multiparticulate taste-masked intermediates.

Taste masking must not block the rapid release required for an orally disintegrating tablet or impair powder spreading.

The manufacturing process becomes part of the product value

The excipient system cannot be assessed independently from the printer, binder, layer thickness, drying conditions, and powder-recovery strategy. A nominally equivalent excipient may fail because it changes bulk density or binder demand.

This expands the market for formulation development services, printer qualification, process analytical technology, and technology-transfer support.

What commercial opportunities exist for excipient suppliers?

Specialty mannitol grades

The highest-value excipient opportunity is likely a mannitol grade optimized for powder-bed printing and orally disintegrating dosage forms. Key product attributes include:

• Narrow particle-size distribution.
• Low and controlled moisture.
• Reliable flow under low shear.
• Consistent bulk density.
• Low variability in surface morphology.
• Acceptable taste and cooling effect.
• Compatibility with aqueous binders.

Suppliers can differentiate through application data showing printability, disintegration, friability, and stability across multiple active ingredients.

Advanced disintegrant systems

Croscarmellose sodium remains a logical benchmark, but commercial development could focus on:

• Co-processed mannitol-disintegrant systems.
• Low-friability superdisintegrants.
• Crosslinked polymers with improved wetting.
• Disintegrants optimized for porous, noncompressed tablets.
• Systems that reduce grittiness at high loading.

The strongest opportunity is a platform excipient that works across multiple ZipDose-like formulations, not a single Spritam copy.

Taste-masking materials

Levetiracetam is a high-volume generic active ingredient, but taste-masked orally disintegrating versions could command a premium in pediatric, geriatric, and dysphagia markets. A taste-masking material must be compatible with rapid disintegration, low residual mouth coating, and high drug loading.

Potential commercial products include coated drug particles, polymeric microcapsules, and resin complexes supplied as ready-to-print powders.

Pharmaceutical-grade flow aids

Colloidal silicon dioxide and similar flow aids can be positioned as process-enabling materials for powder-bed printing. Suppliers should support:

• Powder rheology.
• Segregation resistance.
• Electrostatic behavior.
• Moisture sensitivity.
• Recyclability.
• Impact on disintegration and dissolution.

This is a more defensible commercial position than selling a generic glidant on compendial compliance alone.

Contract development and manufacturing

Aprecia’s technology demonstrates that pharmaceutical 3D printing can reach an approved commercial product. The market opportunity extends to CDMOs offering:

• Dose-form and excipient screening.
• Powder-bed process development.
• Printer scale-up.
• Packaging for fragile porous tablets.
• Stability programs.
• Regulatory CMC documentation.
• Technology transfer for high-dose orally disintegrating products.

The opportunity is strongest for products where conventional tablets create a clear administration problem, such as high-dose drugs, pediatric formulations, and medicines used by patients with swallowing difficulties.

What formulation patents protect Spritam and its manufacturing platform?

Spritam’s differentiation is linked to Aprecia’s ZipDose technology and related 3D-printing know-how. Public patent disclosures around pharmaceutical 3D printing have addressed powder-bed manufacturing, binder deposition, porous dosage forms, and printed pharmaceutical compositions. [3,4]

The practical IP position has several layers:

IP layer	Relevance to commercial competition
Platform patents	May cover printing methods, binder deposition, or dosage-form architecture
Product-specific patents	May cover levetiracetam compositions or dosage-form parameters
Process know-how	Includes powder preparation, printer settings, drying, and inspection
Trade secrets	Can protect formulation ranges and operating windows
Regulatory exclusivity	Protected Spritam’s initial market period but has expired
Trademark and product presentation	Limits confusingly similar branding, not generic formulation entry

Competitors do not necessarily need to use the same excipients or reproduce the same printing process. They may pursue conventional orally disintegrating tablets, freeze-dried tablets, compressed porous tablets, granules, or liquid formulations.

Patent clearance should therefore examine claim scope by jurisdiction, current legal status, terminal disclaimers, continuation practice, and whether claims cover the finished product, the process, or both. A public patent family should not be treated as proof that all claims remain enforceable.

When did Spritam lose regulatory exclusivity?

Spritam did not receive new chemical entity exclusivity because levetiracetam was already approved. FDA granted the product 3-year exclusivity associated with a new clinical investigation supporting the approval of the new dosage form. That exclusivity period expired in 2018. [2,5]

Spritam now competes with generic levetiracetam products, including conventional tablets, oral solutions, and other dosage forms. A generic applicant may seek approval through an ANDA if it can satisfy sameness and bioequivalence requirements for the proposed product. A product that uses a different formulation or delivery technology may require a different regulatory strategy.

What is the Orange Book and Paragraph IV risk for Spritam?

The relevant risk is generic substitution and dosage-form competition, not biosimilar competition. Levetiracetam is a small molecule, so biosimilar pathways do not apply.

An ANDA applicant may challenge listed patents through a Paragraph IV certification if applicable patents remain listed for the reference product. The commercial risk depends on:

• Which patents remain listed.
• Whether patent claims cover the active product, excipients, or manufacturing process.
• Whether the proposed generic uses the same dosage form.
• Whether the applicant can design around the claims.
• Whether the reference sponsor files patent litigation within the statutory period.
• Whether a settlement delays or permits launch.

FDA’s Orange Book should be checked for current patent listings and exclusivity entries. [5] The presence of a patent listing does not establish that the patent will block every alternative formulation. Conversely, a process patent may create a manufacturing barrier even if it does not prevent a different dosage-form approach.

What generic launch scenarios exist for Spritam?

Conventional levetiracetam tablets

This is the lowest-cost competitive route. It does not replicate the orally disintegrating experience and is already widely available.

Generic orally disintegrating tablets

A rival can target the same patient need using conventional ODT technology, including compressed tablets or other porous architectures. This route may avoid dependence on ZipDose but still requires acceptable disintegration, taste, stability, and bioequivalence.

Authorized or licensed 3D-printed products

A partner could license a printing platform or use a technology with a different patent estate. This route may preserve the advantages of high-dose loading and rapid disintegration but requires specialized manufacturing infrastructure.

Pediatric and specialty formulations

Taste-masked granules, oral films, suspensions, or mini-tablets could compete for patients who have difficulty swallowing. These products may have stronger differentiation than a standard generic tablet but face pediatric usability and palatability requirements.

How strong is the Spritam excipient strategy?

The excipient strategy is strong as a process-enabling system but less defensible as a standalone composition. Mannitol, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate are established pharmaceutical excipients. Competitors can usually select alternatives or change concentration ranges unless enforceable claims require a particular combination.

The stronger barriers are likely to be:

1. Validated powder-bed manufacturing know-how.
2. Control of printer and binder parameters.
3. High-dose tablet robustness.
4. Rapid disintegration without excessive friability.
5. Scale-up and yield.
6. Regulatory experience with the platform.
7. Patient familiarity with the product.

For investors and licensors, the platform has more strategic value than any individual excipient. The best commercial target is a repeatable formulation-manufacturing package that can be transferred to multiple high-dose or difficult-to-swallow products.

Key Takeaways

• Spritam uses levetiracetam in a high-dose, orally disintegrating tablet made with Aprecia’s ZipDose 3D-printing technology.
• FDA labeling identifies mannitol, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate as inactive ingredients.
• Mannitol is the central commercial excipient opportunity because it supports bulk, mouthfeel, dissolution, and tablet structure.
• Croscarmellose sodium supports rapid disintegration, while colloidal silicon dioxide supports powder flow and magnesium stearate supports process lubrication.
• The main competitive barrier is the integrated formulation and printing process, not the novelty of the individual excipients.
• Regulatory exclusivity expired in 2018, and conventional generic levetiracetam competition is established.
• Biosimilar risk does not apply because levetiracetam is a small molecule.
• Commercial opportunities include specialty mannitol, advanced disintegrants, taste-masking systems, flow aids, 3D-printing CDMOs, and follow-on high-dose ODT products.
• Generic entrants can design around ZipDose through compressed ODTs, films, granules, liquids, or alternative printing technologies.
• Patent and Orange Book analysis must be performed on current claims and listings rather than inferred from the existence of the ZipDose platform.

FAQs

Can a generic Spritam use different excipients?

Yes. A generic applicant generally does not need to copy every inactive ingredient, provided the product meets applicable sameness, performance, safety, and bioequivalence requirements.

Is mannitol essential to making a Spritam-like tablet?

No. Mannitol is a highly suitable excipient for the product profile, but alternative fillers and co-processed excipients may be possible if they preserve printability, rapid disintegration, strength, and palatability.

Could taste masking increase the commercial value of a levetiracetam ODT?

Yes. Taste masking could improve pediatric and geriatric adoption, but the technology must preserve high drug loading and rapid release.

Is 3D printing required to market a competing levetiracetam orally disintegrating tablet?

No. A competitor can use compressed ODT technology, freeze-drying, films, granules, or other dosage-form platforms, subject to FDA requirements.

What is the best excipient licensing opportunity associated with Spritam?

The strongest opportunity is a formulation-ready excipient platform that combines controlled mannitol, flow enhancement, disintegration, and taste masking for powder-bed printing across multiple active ingredients.

References

1. U.S. Food and Drug Administration. (2015). Spritam (levetiracetam) tablets, prescribing information. Aprecia Pharmaceuticals Company.

2. U.S. Food and Drug Administration. (2015). Approval package for NDA 207958: Spritam (levetiracetam). Center for Drug Evaluation and Research.

3. Aprecia Pharmaceuticals Company. (n.d.). ZipDose technology platform. https://www.aprecia.com

4. Katstra, W. E., Palazzolo, R. D., Rowe, C. W., III, Giritlioglu, B., Teung, P., & Cima, M. J. (2000). Oral dosage forms fabricated by three-dimensional printing. Journal of Controlled Release, 66(1), 1-9.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm